HIV vaccines and methods of using

Abstract

20 26 20 48 99 24 J un 2 02 6 2 0 2 6 2 0 4 8 9 9 2 4 J u n 2 0 2 6 A B S T R A C T

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of Australian Patent Application No. 2022207422, the entire content of which is incorporated herein by reference. 5                          SEQUENCE LISTING

[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is presented in ST.26 format and is based on the Sequence Listing filed for the parent application entitled "HIV vaccines and methods of using". BACKGROUND 10

[0003] HIV remains one of the leading causes of mobility and mortality globally, with over 38 million infected globally and 690,000 deaths in 2019 (UNAIDS. Fact Sheet - World AIDS Day 2020. unaidsorg / en / resources / fact-sheet. 2020). The last three decades have seen significant improvements in therapeutics for HIV. The development of highly active antiretroviral therapy has improved survival for people living with HIV, and reduced morbidity 15 from HIV related immunosuppression and opportunistic infections (Johnson, et al., PLoS Med. 2013;10(4):e1001418; May, et al., AIDS. (2014) 28(8):1193-202; Rodger, et al., AIDS. (2013) 27(6):973-9; Samji, et al., PLoS One. (2013) 8(12):e81355). In recent years antiretroviral treatment (ART) regimens have been simplified to once daily pills with longer acting oral and injectable therapeutics on the horizon (Swindells, et al., N Engl J Med. (2020) 382(12):1112-23; 20 Orkin, et al., N Engl J Med. (2020) 382(12):1124-35; Link, et al., Nature. (2020) 584(7822):614-8). Despite these advances in therapeutics, to date there has only been two well documented examples of cure, both of which required severe immunosuppression and bone marrow transplantation (Gupta, et al., Lancet HIV. (2020) 7(5):e340-e7; Hutter, et al., N Engl J Med. (2009) 360(7):692-8). Unlike many self-limited infectious diseases, the HIV virus 25 integrates itself into its host genome, and establishes latency in resting memory CD4+ T cells (Eisele, et al., Immunity. (2012) 37(3):377-88). These cells form the HIV latent reservoir that cannot be cleared by standard antiretroviral therapy. Reservoir cells are also protected from 2026204899   24 Jun 2026 immune surveillance and clearance mechanisms, as they do not express viral antigens enabling them to evade recognition and clearance by cytotoxic T cells. The reservoir is long-lived and despite detectable reductions in the size of the reservoir, viral rebound is observed following discontinuation of ART (Henrich, etal., Ann Intern Med. (2014) 161(5):319-27; Henrich, et al., 5 J Infect Dis. (2013) 207(11): 1694-702). Activating the reservoir with latency reversing agents will need to be coupled with an effective mechanism to stimulate cytotoxic T cells and eliminate the infected reservoir cells (Ait-Ammar, et al., Front Microbiol. (2019) 10:3060; Mothe, etal., Front Immunol. (2020) 11:823; Fidler, etal., Lancet. (2020) 395(10227):888-98). A therapeutic vaccine designed to generate antigen specific effector T cell responses can be an additional 10 component of an HIV cure strategy.

[0004] T cell vaccines hold significant promise in therapeutic areas such as oncology. High levels of tumor infiltrating CD8+ lymphocytes are associated with better prognosis in some cancers, leading to significant interest in developing vaccines that can induce tumor specific cytotoxic CD8+ T cells. Although previous approaches have had limited success (Rosenberg, et 15   al., Nature Medicine. (2004) 10(9):909-15), the use of novel delivery platforms, improved techniques in antigen discovery and immune modulation hold some promise (Ott, et al., Nature. (2017) 547(7662):217-21). Similarly, T cells play an important role in the control of HIV viremia. Antigen specific T cells that arise in acute HIV infection are responsible for driving the initial drop in viremia (Borrow, et al., J Virol. (1994) 68(9):6103-10; Koup, et al., J Virol. 20   (1994) 68(7):4650-5). HIV infected human long-term non-progressers or elite controllers are characterized by having strong effective antigen specific T cell responses. In SIV infection (a non-human primate model of human HIV infection) antigen specific T cells either generated naturally or through vaccination have been associated with viral control (Schmitz, et al., Science. (1999) 283(5403):857-60; Jin, et al., J Exp Med. (1999) 189(6):991-8). Despite this 25 data, T-cells vaccines for prevention have had limited success in inducing T cell responses of limited breadth or efficacy (Buchbinder, et aL, Lancet. (2008) 372(9653):1881-93; Janes, et al., J Infect Dis. (2013) 208(8): 1231-9; Excler, etal., Curr Opin HIV AIDS. (2016) 11(6):607-13). Therapeutic vaccine trials with T cell vaccines have also shown limited efficacy (Mothe, etal., Front Immunol. (2020) 11:823; Colby, et al., Nature Medicine. (2020) 26(4):498-501). These 30 trials have used viral vectors such as adenoviruses (human and chimpanzee) as well as modified vaccinia Ankara (MVA) virus and with full length viral antigens or shorter constructs (Barouch, et al., Lancet. (2018) 392(10143):232-43; Mothe, et al.,EClinicalMedicine. (2019) 11:65-80). Data from these studies suggest that following vaccination the breadth of antigen specific T cells 2026204899   24 Jun 2026 generated is low. Although these vaccine-induced T cells secrete IFN-y in standard ELISpot assays the demonstrated lack of efficacy suggests that these T cells may not have full cytotoxic activity.

[0005] Immunogen design is a component of any therapeutic HIV vaccine to generate 5 the right antigen specific response, targeted at a conserved region and with cytotoxic activity. Natural infection has demonstrated that the immune response will tend to focus on highly immunodominant variable regions within HIV for example in HIV envelope or Nef, or variable regions in HIV Gag (Addo, et al. J Virol. (2003) 77(3):2081-92; Betts, et al., J Virol. 2001;75(24): 11983-91). These responses generate T cells from which the virus can rapidly 10 escape without a fitness cost (Liu, et al., J Virol. (2006) 80(19):9519-29). An effective HIV vaccine will need to avoid these regions and drive the establishment of de novo responses that focus the immune response to conserved regions of the virus where conservation is required to maintain viral function.

[0006] Previous HIV vaccines have primarily focused on designing immunogens that 15 provide universal coverage by addressing global HIV viral diversity and have generated full length sequences or have adapted algorithms to generate constructs of conserved regions (Korber, et al.. Hum Vaccin Immunother. (2020) 16(3):713-722; Fischer, et al., Nature Medicine. (2007) 13(1):100-6). All of these approaches have primarily evaluated consensus sequences assessing inter patient variability to determine regions of conservation, and 20 concatenated to provide global sequence coverage. However, within an HIV infected individual there are several circulating quasispecies. Some of these viral quasispecies are generated as a result of T cell driven pressure and reflect pre-existing escape route for the virus should a T cell response directed at it emerge (Liu, et al., J Virol. (2006) 80(19):9519-29; Korber, et al., 2020, supra, Price, et al., Proc Natl Acad Sci USA. (1997) 94(5): 1890-5). That the targeting of 25 conserved regions by previous vaccines did not consider quasispecies together with identification of highly conserved immunogenic regions, may in part explain their limited efficacy (Hanke, et al., Expert Rev Vaccines. (2019) 18(10):1029-41). SUMMARY

[0007] Provided are fusion polypeptides comprising a plurality of polypeptide segments 30 of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol and nef. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by HIV-1 genes pol and nef, 2026204899   24 Jun 2026 and does not comprise polypeptide segments encoded by HIV-1 genes env, tat, rev, vpr, vif and / or vpu. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by HIV-1 genes gag, pol and nef, and does not comprise polypeptide segments encoded by HIV-1 genes env, tat, rev, vpr, vif and / or vpu. In some 5 embodiments, the plurality polypeptide segments are derived from conserved regions in a population of viral proteome sequences. In some embodiments, the conserved regions are greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% conserved amongst HIV-1 species in interpatient populations. In some embodiments, the conserved regions are conserved amongst one or more 10   of HIV-1 clades A-K, e.g., one or more of clades A, B, C, D and G, or recombinant forms of one or more of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptides comprise at least 4 and up to 6 polypeptide segments, e.g., 4, 5 or 6 polypeptide segments. In some embodiments, each polypeptide segment is at least 10 amino acids in length, and up to about 225 amino acids in length, e.g. from at least 10 amino acids in length up to 11, 15    12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids in length. In some embodiments, the full-length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids (without a signal peptide) or up to 20 about 550 amino acids (including a signal peptide), e.g., at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids. In some embodiments, the full-length of the fusion polypeptide is no longer than 550 amino acids (with a signal peptide) or no longer than 505 25 amino acids (without a signal peptide), e.g., no longer than 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids. In some embodiments, the full-length of the fusion polypeptide comprises at least 350 amino acids and up to 385 amino acids, e.g., at least 350 amino acids and up to 365 amino acids. 30 In some embodiments, the full-length of the fusion polypeptide comprises at least 390 amino acids and up to 395 amino acids. In some embodiments, each polypeptide segment comprises or consists of one or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises three or more predicted T cell epitopes, e.g., four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises one or more polypeptide 2026204899   24 Jun 2026 segments that bind to or are presented by one or more human HL A class I alleles (e.g. 1, 2, 3, 4, 5 or 6 alleles), e.g. within a single subject or amongst multiple patients. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by at least by a human A*0201 HLA class I molecule. In some embodiments, the fusion 5 polypeptide comprises one or more polypeptide segments that are intracellularly processed and presented by one or more human HLA class II alleles (e.g. 1, 2, 3, 4, 5 or 6 alleles), e.g. within a single subject. In some embodiments, one or more of the polypeptide segments is abutted or fused to an adjacent segment. In some embodiments, one or more of the polypeptide segments is joined to an adjacent segment by one or more peptide linkers. In some embodiments, the one 10 or more peptide linkers is selected from one or more of a polyalanine, a polyglycine, Gln-Glu-Glu (QEE), Lysine (L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), a cleavable linker, a flexible linker, a rigid linker, and combinations thereof. In some embodiments, the flexible linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), Lysine (L), Isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID 15 NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54) and Ser-Glu-Gly (SEG) (SEQ ID NO:55). In some embodiments, the flexible linker comprises a polyalanine linker or a polyglycine linker, e.g., comprising or consisting of 2 or 3 contiguous alanine residues, e.g. AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49) or AAX, wherein X is any amino acid (e.g. A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y) (SEQ ID NO: 50). 20 In some embodiments, the flexible linker comprises or consists of GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58) or GGGS (SEQ ID NO: 59). In some embodiments, the cleavable linker is selected from a 2A cleavable peptide (e.g. foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), a furin recognition / cleavage sequence (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and 25 RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the cleavable linker comprises or consists of a furin recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the cleavable linker comprises or consists of the amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to 30 ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or comprises or consists of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), 2026204899   24 Jun 2026 RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, of the polypeptide segments comprising or consisting of amino acid residues 5 corresponding to Gag 1-53; Gag 147-369; Pol 56-117; Pol 129-320; Pol 367-431 Pol 542-606; Pol 586-606; Pol 683-708, Pol 747-827; Pol 840-909; Pol 840-920; Pol 932-1003; Nef 64-76; Nef 64-99 or Nef 117-148, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not comprise any polypeptide segments corresponding to Gag 54-146; Gag 10   370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828 839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not comprise any polypeptide segments having an amino acid sequence of any one of SEQ ID NOs: 35-47, or 15 fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more, polypeptide segments selected from SEQ ID NOs: 4-33. In some embodiments, the fusion polypeptide 20   comprises or consists of the following polypeptide segments, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively: (a) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708 and Nef 117-148; (b) amino acid residues corresponding to: Pol 56-117; Pol 129-320; Pol 367-431 and Nef 64-99; (c) amino acid residues corresponding to: Pol 542-606; Pol 747-827; Pol 840-920; Pol 932-1003 25 and Nef 64-99; (d) amino acid residues corresponding to: Gag 1-53; Gag 147-369; Pol 683-708; Pol 747-827; Pol 840-920 and Nef 117-148; (e) amino acid residues corresponding to: Pol 56117; Pol 129-320; Pol 367-431; Pol 542-606; Pol 932-1003 and Nef 64-99; (f) amino acid residues corresponding to: Gag 147-369, Pol 586-606, Pol 683-708 and Pol 840-920; (g) amino acid residues corresponding to: Pol 129-320, Pol 747-827, Pol 932-1003 and Nef 64-76; or (h) 30 amino acid residues corresponding to: Gag: 147-369, Pol 747-827, Pol 840-909 and Nef 64-76. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments: (a) SEQ ID NOs: 4, 6, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18 and 32, respectively; (b) SEQ ID NOs: 5, 7, 19 2026204899   24 Jun 2026 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19 and 33, respectively; (c) SEQ ID NOs: 8, 10, 12 and 30 or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 5   94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12 and 30, respectively; (d) SEQ ID NOs: 9, 11, 13 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13 and 31, respectively; (e) SEQ ID NOs: 14, 20, 24, 26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 10   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 20, 24, 26 and 30, respectively; (f) SEQ ID NOs: 15, 21, 25, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, respectively; (g) SEQ ID NOs: 4, 6, 18, 20, 24 and 32, or sequence segments that are at least 15   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18, 20, 24 and 32, respectively; (h) SEQ ID NOs: 5, 7, 19, 21, 25 and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19, 21, 25 and 33, respectively; (i) SEQ ID NOs: 8, 10, 12, 14, 20   26 and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12, 14, 26 and 30, respectively; (j) SEQ ID NOs: 9, 11, 13, 15, 27 and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13, 25   15, 27 and 31, respectively; (k) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (1) SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 30 identical to SEQ ID NOs: 7, 17, 19 and 25, respectively; (m) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; (n) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 2026204899   24 Jun 2026 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively; (o) SEQ ID NOs: 6, 20, 22 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, respectively; (p) SEQ ID NOs: 7, 21, 23 and 29, or sequence 5 segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively; (q) SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (r) SEQ ID NOs: 7, 10   17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively; (s) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, 15 respectively; or (t) SEQ ID NOs: 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments in sequential order, from N-terminus to C-terminus, optionally joined or connected by 20 one or more linkers: SEQ ID NOs: 6, 4, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 4, 18 and 32, respectively; SEQ ID NOs: 7, 5, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID 25 NOs: 7, 5, 33 and 19, respectively; SEQ ID NOs: 12, 30, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively; SEQ ID NOs: 9, 31, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 30 identical to SEQ ID NOs: 9, 31, 13 and 11, respectively; SEQ ID NOs: 14, 26, 20, 30 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 14, 26, 20, 30 and 24, respectively; SEQ ID NOs: 15, 31, 21, 27 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 2026204899   24 Jun 2026 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, respectively; SEQ ID NOs: 32, 18, 4 and 6, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 32, 18, 4 and 6, respectively; SEQ ID NOs: 7, 33, 5 and 19, or 5 sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, respectively; SEQ ID NOs: 8, 30, 12 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 12 and 10, respectively; SEQ ID NOs: 13, 10   31,9 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, respectively; SEQ ID NOs: 26, 30, 14, 20 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 14, 20 and 24, 15 respectively; SEQ ID NOs: 31, 27, 15, 25 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 31, 27, 15, 25 and 21, respectively; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 20 SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 4, 24, 32 and 18, respectively; SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 25   95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively; SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 30   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively; SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, or sequence segments that are 2026204899   24 Jun 2026 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, respectively; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 5   99% identical to SEQ ID NOs: 7, 25, 19, 5, 33 and 21, respectively; SEQ ID NOs: 26, 30, 12, 14, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, respectively; SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively; SEQ ID NOs: 24, 6, 16 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, respectively; SEQ ID NOs: 7, 19, 17 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 15   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 19, 17 and 25, respectively; SEQ ID NOs: 24, 16, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 16, 6 and 18, respectively; SEQ ID NOs: 7, 25, 17 and 19, or sequence segments that are at least 80%, 81%, 20   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 17 and 19, respectively; SEQ ID NOs: 26, 20, 10 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 20, 10 and 28, respectively; SEQ ID NOs: 21, 27, 11 and 29, or sequence segments 25 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 21, 27, 11 and 29, respectively; SEQ ID NOs: 26, 10, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, respectively; SEQ ID NOs: 11, 27, 21 and 29, or 30 sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 27, 21 and 29, respectively; SEQ ID NOs: 22, 6, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 20 and 28, respectively; SEQ ID NOs: 23, 7, 2026204899   24 Jun 2026 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 23, 7, 21 and 29, respectively; SEQ ID NOs: 22, 20, 6 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 5   94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 20, 6 and 28, respectively; or SEQ ID NOs: 7, 21, 23 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 70 10   101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence 15 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223.

[0008] Further provided are compound fusion polypeptides comprising at least a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides 20 being independently selected from the fusion polypeptides as described above and herein. In some embodiments, the compound fusion polypeptide comprises or consists of the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 25   99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 30   97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are 2026204899   24 Jun 2026 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 5 identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 10   98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 15   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 20   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 25   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 30   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 2026204899   24 Jun 2026 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 5   85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 10 SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 20   98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 25   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 30   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the compound fusion polypeptide comprises or consists of the following 2026204899   24 Jun 2026 first fusion polypeptide and second fusion polypeptide in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 5   70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 10 SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 20   98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 25   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 30   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 2026204899   24 Jun 2026 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 5   84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; 10 SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 15 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 20 NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 25 of SEQ ID NOs: 85 and 82, SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 30 of SEQ ID NOs: 86 and 82, SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 2026204899   24 Jun 2026 of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 5   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 10   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are 15 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion 20 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 25   85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID 30 NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 2026204899   24 Jun 2026 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 5   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 10   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 15   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 20   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are 25 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or 30 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ 2026204899   24 Jun 2026 ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 5   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 10   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 15   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 20   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a cleavable linker selected from a 2A 25 cleavable peptide (e.g. foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), a furin recognition / cleavage sequence (e.g. RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a furin 30 recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide are joined or connected by a 2A cleavable peptide comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), 2026204899   24 Jun 2026 RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67, or having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), 5 APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an 10 amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the compound fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 15   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223.

[0009] With respect to further embodiments of the fusion polypeptides and the compound fusion polypeptides, in some embodiments, the fusion polypeptide or the compound fusion polypeptide further comprises an N-terminal signal peptide or leader sequence. In some 20 embodiments, the signal peptide or leader sequence is from a source protein selected from a serum protein, a cytokine, a chemokine, a chaperone protein, an invariant protein, and a protein that directs proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is from a source protein selected from colony stimulating factor 2 (CSF2, GM-CSF), tissue type plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, 25   MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; la-GAMMA, invariant chain), serum albumin (ALB), polyubiquitin B / C (UBB / UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal associated membrane protein 1 (LAMP-1) and lysosomal associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from an 30 amino acid sequence of any one of SEQ ID NOs: 115-126, or an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115-126. In some embodiments, the fusion polypeptide and / or the compound fusion polypeptide are recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptide and / or the 2026204899   24 Jun 2026 compound fusion polypeptide are capable of inducing, promoting or stimulating an immune response in a human. In some embodiments, the fusion polypeptide and / or the compound fusion polypeptide are capable of inducing, promoting or stimulating an immune response against HIV-1 in a human. In some embodiments, the fusion polypeptide and / or the compound fusion 5 polypeptide are capable of inducing, promoting or stimulating proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells and CD4+ T cells.

[0010] Further provided are polynucleotides encoding one or more fusion polypeptides or compound fusion polypeptide, as described above and herein. In some embodiments, the 10 polynucleotide comprises cDNA, mRNA, self-amplifying RNA (SAM, saRNA), self-replicating RNA, or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises self-replicating or self-amplifying alphavirus replicons. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 15   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 167, 210-219 and 225-226. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 20    139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. Further provided are expression cassettes comprising one or more polynucleotides described herein operably linked to one or more regulatory sequences, e.g., a promoter. In some embodiments, the polynucleotide is operably linked to and under the control of a constitutive promoter. In some embodiments, the promoter is selected from a CMV promoter, a CAG promoter and an EFla promoter. 25

[0011] Further provided are lipoplexes, e.g., lipid nanoparticles (LNPs) comprising one or more polynucleotides described herein, e.g., encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 30 NOs: 70-101, 105-112, 200-209, 222-223 and 227, e.g., one or more polynucleotides comprising a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225- 2026204899   24 Jun 2026 226. In some embodiments, the lipoplexes, e.g., lipid nanoparticles (LNPs) comprise one or more polynucleotides described herein, e.g., encoding one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 5   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, e.g., one or more polynucleotides comprising a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 10 NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226.

[0012] Further provided are vectors comprising one or more polynucleotides or one or more expression cassette, described herein. In some embodiments, the vector comprises or consists of one or more polynucleotides encoding one or more fusion polypeptides comprising the following polypeptide segments comprising in sequential order, from N-terminus to C 15   terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 20   15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 25   7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ 30 ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; 2026204899   24 Jun 2026 SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 5 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 10 any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 20   99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 25   97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 30   95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 2026204899   24 Jun 2026 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 5   87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID 10 NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, 15 respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 20   83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 25 SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 30 identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 2026204899   24 Jun 2026 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are 5 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion 10 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 15 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, 20 respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 25   98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide in sequential order, from N-terminus to 30 C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 2026204899   24 Jun 2026 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are 5 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion 10 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 15   76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID 20 NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, 25 respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 30   82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 2026204899   24 Jun 2026 SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 5   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 10   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 15   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that 20 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or 25 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 30   83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; 2026204899   24 Jun 2026 SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 5   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 10   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 15   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 20   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 25   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are 30 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion 2026204899   24 Jun 2026 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 5   98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 10   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 20   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 25   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 30   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 2026204899   24 Jun 2026 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 5 of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 10   99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 15   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 20   99% identical to any one of SEQ ID NOs: 82 and 83, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 25 of SEQ ID NOs: 84 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 30   86 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 2026204899   24 Jun 2026 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 5   95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 10   99% identical to any one of SEQ ID NOs: 82 and 86, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 15 of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 20   83 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 25 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In 30 some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. In some embodiments, the 2026204899   24 Jun 2026 vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 5 of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 10   85 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 15 and 91, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In 20 some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. In some embodiments, the 25 vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the vector comprises one or 30 more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the vector comprises one or more 2026204899   24 Jun 2026 polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 5 and 221, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In 10 some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the 15 vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. In some embodiments, the vector comprises 20 one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the vector comprises one or more 25 polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the vector comprises a polynucleotide encoding a 30 compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the vector comprises a polynucleotide encoding a compound fusion 2026204899   24 Jun 2026 polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the first and second fusion 5 polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the first and second fusion polypeptides do not comprise 10 any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any 15 one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the vector comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 20   152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 25   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 30   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or 2026204899   24 Jun 2026 polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 5   98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 10   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 15   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 20   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 25   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 30   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 2026204899   24 Jun 2026 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 5 any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 10   98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 15   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 20   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 25   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 30   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 2026204899   24 Jun 2026 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 5 NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 10 any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 15   98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising 20 SEQ ID NOs: 130 or SEQ ID NO: 131, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 25   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 132 or SEQ ID 30 NO: 133, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 2026204899   24 Jun 2026 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 139, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 5   94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 142, respectively, and (b) a second polynucleotide comprising 10 SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 15   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first 20 polynucleotide comprising SEQ ID NO: 143, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 143, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ 25 ID NO: 149. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 150, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 30   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 2026204899   24 Jun 2026 99% identical to SEQ ID NO: 151, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153. In some embodiments, the vector comprises the following first polynucleotide and 5 second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 154, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 154, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 10   96%, 97%, 98% or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 155, respectively, and (b) a second polynucleotide comprising 15 SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 20   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first 25 polynucleotide comprising SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ 30 ID NO: 161. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 2026204899   24 Jun 2026 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 5   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first polynucleotide and 10 second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 15   96%, 97%, 98% or 99% identical to SEQ ID NO: 167. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second polynucleotide comprising SEQ ID NO: 20   211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 25   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 30   214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the vector 2026204899   24 Jun 2026 comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second polynucleotide comprising SEQ ID NO: 5   217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 10   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 15   218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the vector 20 comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 25   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first open reading frame and the second polynucleotide encoding the second fusion polypeptide is in 30 a second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first expression cassette and the second polynucleotide encoding the second fusion polypeptide is in a second expression cassette. In some embodiments, the vector 2026204899   24 Jun 2026 is a plasmid vector, a bacterial vector or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication defective, replication deficient, replication attenuated or replication competent. In some embodiments, the viral vector is from a virus 5 selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, maraba virus and vaccinia virus. In some embodiments, the viral vector is from a virus from a taxonomical family selected from Adenoviridae, Arenaviridae, Herpesviridae (e.g. Cytomegalovirus), Poxviridae (e.g. Vaccinia virus, e.g. modified vaccinia Ankara (MVA)), Flaviviridae (e.g. Yellow fever virus), 10 Rhabdoviridae (e.g. Vesiculovirus, e.g. Maraba vesiculovirus), Togaviridae (e.g., Alphavirus, e.g., Venezuelan equine encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV), Cali mammarenavirus (a.k.a., Pichinde mammarenavirus or Pichinde arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus 15 (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from Lymphocytic choriomeningitis mammarenavirus (LCMV) or Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus). In some embodiments, the arenavirus vector comprises a bi-segmented genome. In some embodiments, the arenavirus vector comprises a tri-segmented genome. In 20 some embodiments, the viral vector is a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus or a rhesus adenovirus). In some embodiments, the viral vector is an adenovirus vector selected from adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g. ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 25   (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9), ChAdlO (AdClO), ChAdl 1 (AdCl 1), ChAdl 7 (AdC17), ChAdl6 (AdC16), ChAdl9 (AdC19), ChAd20 (AdC20), ChAd22 (AdC22), ChAd24 (AdC24), ChAdY25, ChAd26 (AdC26), ChAd28 (AdC28), ChAd30 (AdC30), ChAd31 (AdC31), ChAd37 (AdC37), ChAd38 (AdC38), ChAd43 (AdC43), ChAd44 (AdC44), ChAd55 (AdC55), ChAd63 (AdC63), ChAdV63, ChAd68 (AdC68), ChAd73 (AdC73), ChAd82 30   (AdC82), ChAd83 (AdC83), ChAdl43 (AdC143), ChAdl44 (AdC144), ChAdl45 (AdC145), ChAdl47 (AdC147)), gorilla adenovirus (e.g. GC44, GC45, GC46) and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66). 2026204899   24 Jun 2026

[0013] Further provided are host cells comprising one or more polynucleotides, one or more expression cassettes, or one or more vectors, as described herein. In some embodiments, the one or more polynucleotides are not integrated into the host cell genome, e.g., are episomal. In some embodiments, the one or more polynucleotides are integrated into the host cell genome. 5 In some embodiments, the host cell is a mammalian cell, e.g., a human cell. In various embodiments, the host cell can be in vitro or in vivo.

[0014] Further provided are immunogenic compositions. In various embodiments, the immunogenic compositions comprise one or more of the fusion polypeptides or compound fusion polypeptides, one or more polynucleotides, or one or more vectors, as described herein, 10 and a pharmaceutically acceptable carrier. In some embodiments, the immunogenic composition comprises two or more of the fusion polypeptides or compound fusion polypeptides, two or more polynucleotides, two or more vectors, as described herein. In some embodiments, the one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises a first fusion 15 polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID 20 NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13, 25, 23, 15 and 11; SEQ 25 ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8,30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13,31,27, 15 30 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID 2026204899   24 Jun 2026 NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID 5 NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one 10 or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 15   227. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 20   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the immunogenic composition comprises the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined 25 or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 30 identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 2026204899   24 Jun 2026 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 5   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that 10 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or 15 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 20   82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; 25 SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 30 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 2026204899   24 Jun 2026 NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 5   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 10   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 15   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that 20 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 25 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, 30 respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 2026204899   24 Jun 2026 NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion 5 polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 10   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 15   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 20   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 25   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that 30 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or 2026204899   24 Jun 2026 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 5   97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 10   95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 15   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 20   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 25   87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 30   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 2026204899   24 Jun 2026 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 5 SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 10 identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 15   98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 20   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 25   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 30   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 2026204899   24 Jun 2026 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, 5 respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 10   92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 15 SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 20 identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 25   98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 30   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 2026204899   24 Jun 2026 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 5 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, 10 respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 15   101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 20 SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 25   98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides, first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral 30 vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, and (b) a second polynucleotide or second viral vector or second 2026204899   24 Jun 2026 lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, 5 respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more 10 polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides 15 encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second 20 lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 25   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 30   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or 2026204899   24 Jun 2026 more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 5   97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 10   99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) 15 comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or 20 more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral 25 vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or fusion polypeptides 30 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 2026204899   24 Jun 2026 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more 5 polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 20   84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers, SEQ ID NOs: 92 and 93, or 25 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined 30 or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, 2026204899   24 Jun 2026 respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 5   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral 10 vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second polynucleotide or second viral vector or second 15 lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second 20 polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising 25 SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 30   95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 2026204899   24 Jun 2026 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 5   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 10   83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or 15 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more 20 linkers, comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion 25 polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides 30 encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a 2026204899   24 Jun 2026 lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 5   99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 15   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally joined or connected by one or more linkers, comprising SEQ ID NOs: 20   100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 200, or a polypeptide that 25 is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 201, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 30 SEQ ID NO: 201. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 202, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and a second viral vector or a lipoplex (e.g., LNP) comprising a second 2026204899   24 Jun 2026 polynucleotide encoding a second polypeptide comprising SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a 5 first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 204, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 10   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 105, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 15 SEQ ID NO: 105, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 107, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a 20 first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 206, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 207, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 25   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 208, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 30 SEQ ID NO: 208, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector 2026204899   24 Jun 2026 or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second 5 polynucleotide encoding a second polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or a lipoplex (e.g., LNP) comprising a first polynucleotide encoding a first polypeptide 10 comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or a lipoplex (e.g., LNP) comprising a second polynucleotide encoding a second polypeptide comprising SEQ ID NO: 223, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 20   210-219 and 225-226. In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 25   142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 30   99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 2026204899   24 Jun 2026 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or 5 polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 10 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ 15 ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 20 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 25 NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 30 any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 2026204899   24 Jun 2026 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 5   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or 10 polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 15 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ 20 ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 25 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 30 NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 2026204899   24 Jun 2026 any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 5   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 10   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or 15 polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 20   225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g, LNPs) comprising the following first polynucleotide and second 25 polynucleotide: (a) a first vector or first lipoplex (e.g, LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides 30 comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g, LNPs) comprising the following first polynucleotide 2026204899   24 Jun 2026 and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, 5 and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first 10 and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 15 and 146, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors of such an immunogenic composition 20 are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or 25 polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 30   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors of such an immunogenic composition are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral 2026204899   24 Jun 2026 vectors or first and second lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 5   95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively, and (b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some 10 embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to SEQ ID NO: 160, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral 20 vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a 25 polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral 30 vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 2026204899   24 Jun 2026 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., 5 LNP) comprising a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166, respectively, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 10   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 15   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the immunogenic 20 composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) the 25 second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or 30 more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 2026204899   24 Jun 2026 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral 5 vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 15   84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the immunogenic 20 composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) the 25 second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or 30 more polynucleotides: (a) the first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) the second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 2026204899   24 Jun 2026 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a compound fusion polypeptide, a vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion 5 polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the immunogenic composition comprises a compound fusion polypeptide, a 10 vector or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some 15 embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 andNef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or 20 more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In various embodiments of the immunogenic compositions, 25 the first and second viral vectors can be Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the immunogenic composition comprises a single vector comprising one or more polynucleotides encoding first and second fusion polypeptides. In some embodiments, the 30 immunogenic composition further comprises one or more of an adjuvant, a detergent, a micelle forming agent, and an oil. In some embodiments, the immunogenic composition is formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal and mucosal (e.g. buccal, intranasal, intrarectal, intravaginal). In some 2026204899   24 Jun 2026 embodiments, the immunogenic composition is formulated as a liquid, a suspension or an emulsion. In some embodiments, the immunogenic composition is lyophilized.

[0015] Further provided are kits comprising one or more unitary doses of one or more of the fusion polypeptides, one or more compound fusion polypeptides, one or more 5 polynucleotides, one or more vectors, or one or more immunogenic compositions, as described herein. In some embodiments, the kit comprises two or more of the fusion polypeptides, two or more compound fusion polypeptides, two or more polynucleotides, two or more vectors, or two or more immunogenic compositions, as described herein. In some embodiments, the one or more unitary doses are in a single container. In some embodiments, one or more unitary doses 10 are in two or more separate containers. In some embodiments, the kit comprises one or more containers selected from vials, ampules and pre-loaded syringes. In some embodiments, the kit comprises one or more containers comprising the one or more fusion polypeptides, one or more polynucleotides or one or more vectors in an aqueous solution. In some embodiments, the one or more unitary doses are the same. In some embodiments, the one or more unitary doses are 15 the different. In some embodiments, the kit comprises one or more unitary doses of one or more viral vectors and the unitary doses are in the range of about 103 to about 1012 viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g. from about 104 to about 107 viral FFU or PFU or IU or vp, e.g. from about 103 to about 104, 105, 106, 107, 108, 109, 1010, 1011, 1012,1013, 1014 or 1015 viral FFU or PFU or IU or vp. In some 20 embodiments, the kit comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, the first and second polypeptides comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID 25   NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15, 25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ 30   ID NOs: 9, 13, 25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8,30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 2026204899   24 Jun 2026 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 5   10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15,31,9,27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 10   11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the kit comprises one or more fusion polypeptides, one or more 15 vectors, or one or more lipoplexes (LNPs), comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 20   222-223 and 227. In some embodiments, the kit comprises one or more fusion polypeptides, one or more vectors, or one or more lipoplexes (LNPs), comprising one or more polynucleotides encoding one or more fusion polypeptides, comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 25   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 and 71, or fusion 30 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 2026204899   24 Jun 2026 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 5   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 10   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 15   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 20   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 25   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 30   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 2026204899   24 Jun 2026 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 5 of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 10   99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 15   97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 20   95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 25   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 30   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 2026204899   24 Jun 2026 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 5 any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the kit comprises the following first fusion polypeptide and second fusion polypeptide, one or more vectors, or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, in sequential order, from N-terminus to C-terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 70 10 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; 15 SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 20 and 72, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 25 NOs: 75 and 74, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one 30 of SEQ ID NOs: 77 and 76, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 2026204899   24 Jun 2026 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or fusion polypeptides that are at least 80%, 5   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 83 and 82, or fusion polypeptides that are 10 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 85 and 84, or fusion 15 polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 87 and 20   86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID 25 NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, 30 respectively; SEQ ID NOs: 85 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 2026204899   24 Jun 2026 82 and 86, respectively; SEQ ID NOs: 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 5   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 10   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 87 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 83, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 15   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 87 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 20   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 87 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that 25 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or 30 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; SEQ ID NOs: 2026204899   24 Jun 2026 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 101 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 5   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 91 and 90, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; SEQ ID NOs: 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 15   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 20   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; SEQ ID NOs: 97 and 96, or fusion polypeptides that are at least 80%, 81%, 25   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 96 and 94, or fusion polypeptides that are at least 30   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 97 and 95, or fusion polypeptides that 2026204899   24 Jun 2026 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively; SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 5   98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 10   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 15   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; SEQ ID NOs: 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 20   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; SEQ ID NOs: 99 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively; SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 25   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or SEQ ID NOs: 101 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the kit comprises first, second, third and 30 fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 2026204899   24 Jun 2026 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or fusion polypeptides 5 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 10   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more 20 polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 25 and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 30 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 2026204899   24 Jun 2026 identical to any one of SEQ ID NOs: 82 and 85, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 5   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more 10 polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 15 and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 20 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 200, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and (b) a second viral vector or 25 lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 201, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 30 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 202, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and (b) a second viral vector or 2026204899   24 Jun 2026 lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 203, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the kit comprises first and second viral vectors or 5 lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 204, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 10   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 204, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 205, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205. In some embodiments, the kit comprises first and second viral vectors or 15 lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 105 or 206, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 20   94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 107 or 207, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207, respectively. In some embodiments, the 25 kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 208, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 30   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and (b)a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some 2026204899   24 Jun 2026 embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide 5 comprising SEQ ID NO: 222, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b)a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 10   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide 15 encoding a fusion polypeptide comprising SEQ ID NO: 222, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 223, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 20   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more 25 polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 30 and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising 2026204899   24 Jun 2026 SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 5 and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the 10 following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, 20 respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or 25 lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral 30 vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 2026204899   24 Jun 2026 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or fusion polypeptides 5 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 10   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more 20 polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 25 and a second fusion polypeptide comprising SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 30 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 2026204899   24 Jun 2026 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 5   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more 10 polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following 15 first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first 20 fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 25   99% identical to any one of SEQ ID NOs: 94 and 95, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 30 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising 2026204899   24 Jun 2026 SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively, and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide 5 and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the 10 following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 15 identical to any one of SEQ ID NOs: 94 and 96, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, 20 respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; and (d) a fourth viral vector or 25 lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit comprises first, second, third and fourth viral 30 vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 2026204899   24 Jun 2026 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or fusion polypeptides 5 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 10   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 15   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In various embodiments of the kits, the viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the kit comprises a 20 polynucleotide comprising or consisting of a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219 and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130-167, 210-219 and 225-226. In some embodiments, the kit comprises a polynucleotide comprising or consisting of a nucleic acid sequence of any one of 25 SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225 and 226. In some embodiments, the kit comprises the following first polynucleotide and second polynucleotide, one or more 30 vectors, or one or more lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 2026204899   24 Jun 2026 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, 5 respectively; SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 10 NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 15 any one of SEQ ID NOs: 133 and 137, respectively; SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively; SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 20   98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 25   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 30   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 2026204899   24 Jun 2026 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ 5 ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 10 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 15 NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 20 any one of SEQ ID NOs: 152 and 158, respectively; SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 25   98% or 99% identical to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 30   96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 2026204899   24 Jun 2026 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; SEQ ID NOs: 166 5 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively; SEQ 10 ID NOs: 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 15 and 215, respectively; SEQ ID NOs: 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; SEQ ID NOs: 218 and 219, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 20 NOs: 218 and 219, respectively; SEQ ID NOs: 218 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 25 any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 30   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some 2026204899   24 Jun 2026 embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 5   89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively. 10 In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to 15 any one of SEQ ID NOs: 131 and 135, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second 20 polynucleotides comprising SEQ ID NOs: 139 and 145, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 25   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 30   81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 2026204899   24 Jun 2026 identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors are Lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first 5 vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID 10 NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Cali mammarenavirus (a.k.a. Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the kit comprises 15 first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, 20 respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 25 and 152, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 30   94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the kit comprises first, second, third and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or that are 2026204899   24 Jun 2026 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 155 and 158, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 5   86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, 10 respectively; and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In various embodiments, one or more of the first, second, third and fourth vectors are adenoviral vectors. In some 15 embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID 20 NOs: 160 and 161, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 162 and 163, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. In some embodiments, the kit comprises first and second viral vectors comprising the following 25 first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively, and (b) a second vector or lipoplex (e.g., LNP) comprising first and 30 second polynucleotides comprising SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 2026204899   24 Jun 2026 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 5   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide 10 comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 15   91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a 20 first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 25   95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide 30 comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 2026204899   24 Jun 2026 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. 5 In some embodiments, the kit comprises (a) a first vector or lipoplex (e.g., LNP) comprising a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at 10 least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the kit comprises a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 105-112, 20015   209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223 and 227. In some embodiments, the kit comprises a compound fusion polypeptide, a vector, or a lipoplex (e.g., LNP) comprising a polynucleotide encoding a compound fusion polypeptide, the compound 20 fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 209, 222 and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 209, 222 and 223. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments corresponding to Gag 54-146; 25 Gag 370-500; Pol 1-55; Pol 118-128; Pol 321-366; Pol 432-541; Pol 607-682; Pol 709-746; Pol 828-839; Pol 921-931; Nef 1-63; Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the Gag, Pol and Nef amino acid position numbers correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or more fusion polypeptides do not comprise any polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or 30 fragments or subsequences thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the kit further comprises one or more unitary doses of one or more additional therapeutic agents. In some embodiments, the kit comprises one or more agents that activate 2026204899   24 Jun 2026 latent HIV, e.g., one or more latency reversing agents (LRAs). In some embodiments, the kit comprises one or more LRAs selected from agonists or activators of one or more toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, 5 inhibitor of apoptosis proteins (IAP) antagonists, and second mitochondria-derived activator of caspases (SMAC) mimetics. In some embodiments, the kit comprises one or more agonists or activators of one or more toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist and a TLR9 agonist. In some embodiments, the TLR7 agonist is 10 selected from GS 9620 (vesatolimod), R848 (Resiquimod), DS-0509, LHC-165 and TMX-101 (imiquimod), and / or wherein the TLR8 agonist is selected from GS-9688 (Selgantolimod), R848 (Resiquimod) and NKTR-262 (dual TLR7 / TLR8 agonist). In some embodiments, the kit comprises one or more interleukin receptor agonists of an interleukin selected from IL-2, IL-7, IL-12 and IL-15. In some embodiments, the kit comprises one or more cytokines selected from 15   IL-2, IL-7, IL-12, IL-15, and variants thereof. In some embodiments, the kit comprises one or more innate immune activators. In some embodiments, the one or more innate immune activators comprises an agonist of a receptor selected from firns related tyrosine kinase 3 (FLT3), stimulator of interferon genes (STING) receptor, DExD / H-box helicase 58 (DDX58; a.k.a.. RIG-I), nucleotide binding oligomerization domain containing 2 (NOD2). In some 20 embodiments, the kit comprises an agonist of fms related tyrosine kinase 3 (FLT3). In some embodiments, the kit comprises one or more antagonists or inhibitors of an inhibitory immune checkpoint protein or receptor and / or one or more activators or agonists of a stimulatory immune checkpoint protein or receptor. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD27, CD70; CD40, CD40LG; CD47, 25 CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD 160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); 30 HERV-H LTR-associating 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILRI), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 2026204899   24 Jun 2026 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, 5   PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, GDI 12); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular 10 receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); ULI6 binding protein 1 (ULBP1); ULI6 binding protein 2 (ULBP2); ULI6 binding protein 3 (ULBP3); retinoic acid early transcript IE 15 (RAET1E; ULBP4); retinoic acid early transcript IG (RAET1G; ULBP5); retinoic acid early transcript IL (RAET1L; ULBP6); lymphocyte activating 3 (CD223); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor Cl (KLRC1, NKG2A, CD159A); killer cell lectin like receptor KI (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C); killer cell 20 lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long 25 cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor DI (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T-cell inhibitory immune checkpoint proteins or receptors are selected from CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, 30   CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD 152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain 2026204899   24 Jun 2026 containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, 5 two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit comprises one or more agonists or activators of one or more T-cell 10 stimulatory immune checkpoint proteins or receptors. In some embodiments the T-cell stimulatory immune checkpoint proteins or receptors are selected from CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), 15 TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD 155). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK-cell inhibitory immune checkpoint proteins or receptors are selected from killer cell immunoglobulin 20 like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 25   1 (KIR3DL1); killer cell lectin like receptor Cl (KLRC1, NKG2A, CD159A); and killer cell lectin like receptor DI (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK-cell stimulatory immune checkpoint proteins or receptors are selected from CD16, CD226 (DNAM-1); killer cell lectin like receptor KI 30 (KLRK1, NKG2D, CD314); and SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the kit comprises and antibody that binds to CTLA4. In some embodiments, the proteinaceous or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS- 2026204899   24 Jun 2026 986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 5   (CTLA4 / PD-1). In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ- 10   63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR- 1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4 / PD-L1 / CD28), PF- 15   06936308 (PD-1 / CTLA4), MGD-013 (PD-l / LAG-3), FS-118 (LAG-3 / PD-L1) MGD-019 (PD- 1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-l / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-Ll / TGFp-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1). In some embodiments, the one or more immune checkpoint inhibitors 20 comprises a small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 orPDCDl is selected from GS-4224, GS-4416, INCB086550 andMAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. In some embodiments, the kit further comprises one or more antiviral agents. In some embodiments, the 25 one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors and capsid inhibitors.

[0016] Further provided are methods for eliciting an immune response to human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the 30 subject a fusion polypeptide, a compound fusion polypeptide, a polynucleotide, a vector, a lipoplex (e.g., LNP) or an immunogenic composition, as described herein. Also provided are methods of treating or preventing human immunodeficiency virus (HIV) in a subject in need thereof, comprising administering to the subject a fusion polypeptide, a compound fusion 2026204899   24 Jun 2026 polypeptide, a vector, a lipoplex (e.g., LNP) or an immunogenic composition, as described herein. In some embodiments the method entails administering a single vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more compound fusion 5 polypeptides, two or more polynucleotides encoding the fusion polypeptides, two or more viral expression vectors comprising polynucleotides encoding the fusion polypeptides, two or more lipoplexes (e.g., LNPs) or two or more immunogenic compositions, as described herein, are administered to the subject simultaneously or concurrently. In some embodiments, two or more fusion polypeptides, or two or more polynucleotides or two or more viral expression vectors 10 encoding the fusion polypeptides, are in the form of a bivalent antigen composition. In some embodiments, the method entails administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more lipoplexes (e.g., LNPs), the first and second polypeptides 15 comprising the following polypeptide segments, in sequential order, from N-terminus to C terminus, optionally joined or connected by one or more linkers: SEQ ID NOs: 6, 4, 16 and 26, and SEQ ID NOs: 7, 5, 27 and 17; SEQ ID NOs: 12, 24, 8 and 10, and SEQ ID NOs: 9, 25, 13 and 11; SEQ ID NOs: 14, 22, 18, 24 and 20, and SEQ ID NOs: 15,25, 19, 23 and 21; SEQ ID NOs: 26, 16, 4 and 6, and SEQ ID NOs: 7, 27, 5 and 17; SEQ ID NOs: 8, 24, 12 and 10, and 20 SEQ ID NOs: 13, 25, 9 and 11; SEQ ID NOs: 22, 24, 14, 18 and 20, and SEQ ID NOs: 25, 23, 15, 21 and 19; SEQ ID NOs: 20, 6, 4, 18, 16 and 26, and SEQ ID NOs: 7, 19, 5, 21, 27 and 17; SEQ ID NOs: 8, 24, 14, 12, 22 and 10, and SEQ ID NOs: 9, 13,25, 23, 15 and 11; SEQ ID NOs: 18, 26, 20, 4, 6 and 16, and SEQ ID NOs: 7, 21, 17, 5, 27 and 19; SEQ ID NOs: 22, 24, 12, 14, 8 and 10, and SEQ ID NOs: 15, 25, 9, 23, 13 and 11; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and 25 SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 7, 21, 5, 25, 33 and 19; SEQ ID NOs: 24, 6, 4, 20, 18 and 32, and SEQ ID NOs: 8, 30, 14, 12, 26 and 10; SEQ ID NOs: 8, 30, 14, 12, 26 and 10, and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 6, 20, 4, 24, 32 and 18, and SEQ ID NOs: 8, 12, 30, 26, 14 and 10; SEQ ID NOs: 7, 21, 5, 25, 33 and 19 and SEQ ID NOs: 9, 13, 31, 27, 15 and 11; SEQ ID NOs: 20, 32, 24, 4, 6 and 30   18, and SEQ ID NOs: 26, 30, 12, 14, 8 and 10; SEQ ID NOs: 7, 25, 19, 5, 33 and 21, and SEQ ID NOs: 15, 31, 9, 27, 13 and 11; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 20, 10 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 26, 10, 20 and 28; SEQ ID NOs: 24, 6, 16 and 18, and SEQ ID NOs: 7, 25, 17 and 19; SEQ ID NOs: 7, 19, 17 and 25, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 24, 16, 6 and 18, and SEQ ID NOs: 27, 11, 21 and 29; 2026204899   24 Jun 2026 SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 11, 27, 21 and 29; SEQ ID NOs: 7, 25, 17 and 19, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 20 and 28, and SEQ ID NOs: 23, 7, 21 and 29; SEQ ID NOs: 22, 20, 6 and 28, and SEQ ID NOs: 7, 21, 23 and 29; SEQ ID NOs: 26, 10, 20 and 28, and SEQ ID NOs: 21, 27, 11 and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26 5 and 10; or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the method entails administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), the one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID 10 NOs: 70-101, 105-112, 200-209, 222-223 and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222223 and 227. In some embodiments, the method entails administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or 15 more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), the one or more fusion polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% 20 identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209 and 222-223. In some embodiments, the method entails administering the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides, one or more vectors or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally joined or connected by one or 25 more linkers: SEQ ID NOs: 70 and 71, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 30   72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of 2026204899   24 Jun 2026 SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 5   85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 10   82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 15   80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 82 and 86, or fusion polypeptides that 20 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; SEQ ID NOs: 83 and 87, or 25 fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 30   88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; 2026204899   24 Jun 2026 SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 5   90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 10   88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% id...

Claims

1. A method of designing a fusion polypeptide that is capable of eliciting animmune response against one or more viral target antigens, the method comprising:a) identifying in silico one or more regions of sequence conservation in a population of polypeptide sequences encoded by a viral gene, the population from an interpatient virus population;b) identifying in silico the two most prevalent polypeptide sequences from the one or more conserved regions identified in step a), and generating multivalent polypeptide segments from the conserved regions; andc) arranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments.

2. The method of claim 1, wherein step (c) comprises reducing or eliminatingjunctional 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments.

3. A method of designing a fusion polypeptide that is capable of eliciting animmune response against one or more viral target antigens, the method comprising:a) identifying in silico one or more regions of sequence conservation in a first population of polypeptide sequences encoded by a viral gene, the first population from an interpatient virus population;b) optionally, identifying in silico the two most prevalent polypeptide sequences from the one or more conserved regions identified in step a); andc) arranging the retained polypeptide segments into one or more contiguous fusion polypeptides, such that the junctions connecting the polypeptide segments avoid or reduce creating epitopes capable of binding human MHC class I or human MHC class II molecules, e.g., with a predicted binding affinity IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments.2026204899   24 Jun 20264.     The method of any one of claims 1 to 3, wherein step (c) comprisesreducing or eliminating viral polypeptide 9-mers that have at least 55% (5 of 9 amino acid residues), e.g., at least 65% (6 of 9 amino acid residues), e.g., at least 75% (7 of 9 amino acid residues), e.g., at least 85% (8 of 9 amino acid residues), amino acid sequence identity to a human protein.

5. The method of any one of claims 1 to 4, wherein the multivalentpolypeptide segments are bivalent polypeptide segments.

6. The method of any one of claims 1 to 5, further comprising the step ofidentifying variant subsequences within one or more regions of sequence conservation in an intrapatient population of polypeptide sequences encoded by a viral gene, e.g., using deep sequencing data.

7. The method of claim 6, further comprising the step of identifyingconserved regions of a polypeptide encoded by a viral gene, such that at least 70% of the variant subsequences within the one or more regions of sequence conservation in the intrapatient population are within the bivalent polypeptide segments.

8. The method of any one of claims 1 to 7, further comprising the step ofshortening the length of the fusion polypeptide, e.g., by at least 10%, 15%, 20%, 25%, 30%, or more, retaining polypeptide segment subsequences comprising epitopes (i) predicted in silico, and (ii) confirmed in vitro.

9. A method for producing a multivalent antigen, the method comprisingconstructing, in silico, a set of multivalent amino acid sequences within structurally conserved regions of a population of viral proteome sequences by a method comprising (a) aligning the population of viral proteome sequences;(b) creating, for each sequence in the alignment, a set of 9-amino acid subsequences (“9-mers”) starting with the N-terminal amino acid, each subsequence overlapping the preceding subsequence by eight amino acids such that each sequence of length l in the alignment contains (l-8) 9-mers;2026204899   24 Jun 2026(c) calculating a frequency for each unique 9-mer starting at a position i in each sequence of the alignment and identifying the two or more most common unique 9-mers at each position;(c)(1) wherein frequency is calculated as the number of times the unique 9-mer occurs at position i in the alignment divided by the total number of sequences in the alignment;(d) calculating a multivalent conservation for each position by summing the proportion of sequences in the alignment containing either of the two or more most common unique 9-mers;(e) creating an alignment of conserved regions by extracting the sequences in the alignment having a multivalent conservation of greater than 80% or greater than 90%;(f) determining a frequency for each pair of unique 9-mers at each position in the alignment of conserved regions;(g) connecting 9-mer pairs in adjacent positions of the alignment of conserved regions that share an overlap of eight amino acids;(h) creating a directed acyclic graph in which each 9-mer pair is a node and the edges between adjacent nodes are formed from the connected 9-mer pairs in the adjacent positions with the weight of each edge equal to the frequency of the downstream 9-mer pair,• adding a source node and connecting it with all of the nodes in the first position,• adding a sink node and connecting it with all of the nodes in the last position, and• negating all of the weights;(i) finding an optimal path in the directed acyclic graph from the source node to the sink node where the optimal path is defined in terms of the sum of the frequencies of all 9-mer pairs in the directed acyclic graph;(j) building a multivalent antigen by connecting two or more 9-mers in adjacent positions within the optimal multivalent 9-mer path if they share an overlap of eight amino acids, thereby creating two or more sequences of connected 9-mers which together form the multivalent antigen; and2026204899   24 Jun 2026(k) optionally, rearranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments.

10. The method of claim 9, wherein the multivalent conservation is bivalent conservation and wherein the multivalent antigen is a bivalent antigen.

11. The method of claim 9 or claim 10, wherein in step (a) the conserved regions are further defined by performing one or more of the following steps:(i) removing segments of fewer than 35 amino acids in length, e.g., from 9 amino acids to 10, 15, 20, 25, 30 or 35 amino acids in length;(ii) removing segments determined to have less than 90% multivalent (e.g., bivalent) conservation;(iii) removing segments determined to be weakly immunogenic or non-immunogenic, e.g., as demonstrated in in vitro or in vivo; and / or(iv) including additional segments determined to be immunogenic, e.g., as demonstrated in in vitro or in vivo.

12. The method of any one of claims 9 to 11, wherein the step of rearranging the peptide segments to reduce or avoid creation of deleterious epitopes is performed by a method comprising one or more of in silico HLA binding analysis and human proteome crossrecognition analysis.

13. The method of any one of claims 9 to 12, further comprising inserting a linker sequence between one or more adjacent segments.

14. The method of any one of claims 9 to 13, wherein the method further comprises improving the multivalent (e.g., bivalent) antigen produced in step (h) by removing junctional 9-mers that bind to a specific HLA allele with a predicted IC50 value of less than about 1000 nM or having a percentile rank within the top 5% in a population of polypeptide segments.

15. The method of any one of claims 9 to 14, wherein the method further comprises improving the multivalent (e.g., bivalent) antigen produced in step (h) by removing 9-mers that have at least 55% (5 of 9 amino acid residues), e.g., at least 65% (6 of 9 amino acid2026204899   24 Jun 2026residues), e.g., at least 75% (7 of 9 amino acid residues), e.g., at least 85% (8 of 9 amino acid residues), amino acid sequence identity with human peptides or that have the same T cell receptor (TCR) facing residues with human proteins.

16. The method of any one of claims 9 to 15, further comprising rearranging the polypeptide segments to reduce or avoid the creation of deleterious epitopes at junctions between polypeptide segments.

17. The method of claim 16, wherein the step of rearranging the peptide segments to reduce or avoid creation of deleterious epitopes is performed by a method comprising one or more of in silico HLA binding analysis and human proteome crossrecognition analysis.

18. The method of any one of claims 9 to 17, further comprising the step of identifying variant subsequences within one or more regions of sequence conservation in an intrapatient population of polypeptide sequences encoded by a viral gene, e.g., using deep sequencing data.

19. The method of claim 18, further comprising the step of identifying conserved regions of a polypeptide encoded by a viral gene, such that at least 70% of the variant subsequences within the one or more regions of sequence conservation in the intrapatient population are within the bivalent polypeptide segments.

20. The method of any one of claims 9 to 19, further comprising the step of shortening the length of the fusion polypeptide, e.g., by at least 10%, 15%, 20%, 25%, 30%, or more, retaining polypeptide segment subsequences comprising epitopes (i) predicted in silico, and (ii) confirmed in vitro.

21. The method of any one of claims 1 to 20, wherein the one or more viral target antigens are from a mammalian virus, e.g., a human virus.

22. The method of any one of claims 1 to 21, wherein the one or more viral target antigens are from a virus selected from human immunodeficiency virus (HIV), hepatitis B2026204899   24 Jun 2026virus (HBV), human papillomavirus (HPV), herpes simplex virus (HSV), Ebola virus, Zika virus and Chikungunya virus.

23. The method of any one of claims 1 to 22, wherein the interpatient virus population is from a population of patients who have not received antiretroviral therapy (ART).

24. The method of any one of claims 1 to 22, wherein the interpatient virus population is from a population of patients who have received antiretroviral therapy (ART).

25. A fusion polypeptide made according to the method of any one of claims 1 to 24, wherein the fusion polypeptide elicits an immune response against a virus in a mammal, e.g., a human.

Images